Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for ovarian cancer. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist case presentations
• Interactive audience polling and extensive Q&A

Module 1: Management of Newly Diagnosed Ovarian Cancer

Module 2: PARP Inhibitors in the Management of Relapsed Disease

Target Audience
These activities are intended for gynecologic oncologists, medical oncologists, gynecologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of ovarian cancer (OC).

Learning Objectives

• Appraise guideline recommendations, consensus statements and clinical investigator perspectives regarding the indications for and selection of genetic testing platforms in OC, and use the results of these assessments to guide long-term treatment.
• Recognize the FDA approval of olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with advanced OC harboring a deleterious or suspected deleterious BRCA germline or somatic mutation, and appropriately integrate this agent into clinical care.
• Review emerging trial data evaluating niraparib as maintenance therapy in the first-line setting for patients with or without BRCA mutations, and consider the clinical and research implications of these findings.
• Understand the biologic rationale for and available data with the use of PARP inhibitors in combination with anti-angiogenic agents, and discern how this strategy may affect therapeutic algorithms in the near future.
• Appreciate available clinical trial data with PARP inhibition in combination with front-line chemotherapy and then as maintenance treatment for patients with newly diagnosed OC, and evaluate the potential role of this novel therapeutic approach.
• Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for patients with recurrent, platinum-sensitive and multiregimen-refractory OC in order to personalize care plans incorporating these agents.
• Recognize the toxicities associated with PARP inhibitors commonly used in the care of patients with OC, and offer supportive management strategies to minimize or ameliorate these side effects.
• Develop an understanding of the rationale for, emerging data with and potential clinical roles of combining PARP inhibitors with anti-PD-1/PD-L1 antibodies, and counsel appropriate patients about the availability of and participation in research studies.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Additional faculty disclosures to be provided. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Armstrong — Advisory Committee: AbbVie Inc, Cue Biopharma, Eisai Inc; Contracted Research: Advaxis Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Pfizer Inc, Syndax Pharmaceuticals Inc, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, DUO-O, DUO-E trials. Dr Banerjee — Consulting Agreements, Advisory Boards and Lectures: Amgen Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Epsilogen, Genmab, GlaxoSmithKline, ImmunoGen Inc, Merck Serono, Merck Sharp & Dohme Corp, Mersana Therapeutics, Pfizer Inc, Roche Laboratories Inc, Tesaro, A GSK Company; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Tesaro, A GSK Company, Verastem Inc. Dr Coleman — Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Janssen Biotech Inc, Merck, Novocure, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Genentech, a member of the Roche Group, Janssen Biotech Inc, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, VBL Therapeutics. Dr Dizon — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GlaxoSmithKline, Regeneron Pharmaceuticals Inc; Contracted Research: Bristol-Myers Squibb Company, GlaxoSmithKline, Kazia Therapeutics Limited; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Regeneron Pharmaceuticals Inc. Dr Herzog — Advisory Committee: Aravive Inc, AstraZeneca Pharmaceuticals LP, Caris Life Sciences, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Gradalis Inc, GlaxoSmithKline, Merck; Data and Safety Monitoring Board/Committee: Corcept Therapeutics, Incyte Corporation. Prof Ledermann — Advisory Committee: Amgen Inc, Artios Pharma, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, GlaxoSmithKline, Merck Sharp & Dohme Corp, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme Corp; Data and Safety Monitoring Board/Committee: Regeneron Pharmaceuticals Inc; Speaker’s Bureau: AstraZeneca Pharmaceuticals LP, Clovis Oncology, GlaxoSmithKline, Merck Sharp & Dohme Corp. Dr Matulonis — Consulting Agreements: Merck, Novartis; Data and Safety Monitoring Board/Committee: Advaxis Inc, Symphogen A/S; Scientific Advisory Board: Clarity Pharmaceuticals, Ovarian Cancer Research Alliance, Rivkin Foundation. Dr Moore — Advisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners. Dr Westin — Consulting Agreements: AstraZeneca Pharmaceuticals LP, Circulogene, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Merck, Novartis, Pfizer Inc, Tesaro, A GSK Company, Zentalis Pharmaceuticals; Contracted Research: ArQule Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Cotinga Pharmaceuticals, Genentech, a member of the Roche Group, Novartis, Tesaro, A GSK Company; Data and Safety Monitoring Board/Committee: Xenetic Biosciences Inc.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by an educational grant from GlaxoSmithKline.